The description of the sigma-1 receptor came about as a binding site for a subtype of opioid receptors which was soon rectified as a non-opioid receptor of its own. It has been 33 years after the first description of the sigma-1 receptor during which period the receptor has been demonstrated to be a protein with many never-before described features. The reason for this uniqueness of the sigma-1 receptor is partly due to the fact that its sequence does not resemble that of any mammalian proteins, leading to the situation that no pre-existing description could be followed in searching for its potential physiological roles. It is also because of this uniqueness of the sigma-1 receptor that opens up opportunities to search for its functions in many physiological systems particularly as they may relate to human diseases. It is thus a great pleasure to see that the Journal of Pharmacological Sciences is devoting a special issue in the beginning of year 2015 to focus on the sigma-1 receptor research.

The sigma-1 receptor has so far been implicated in diseases including Alzheimer's disease, Parkinson's disease, psychostimulant addiction, cancer, myocardial hypertension, aging, cognition, depression, fronto-temporal lobar motor neuron degeneration, amyotrophic lateral sclerosis, and HIV-associated neural dementia. As sigma-1 receptors exist in immune systems, functions of sigma-1 receptors in certain immune system have also been reported in the literature. This plethora of involvement of sigma-1 receptors in so many different types of diseases raises a fundamental question: what is the mode of action of the sigma-1 receptor that relates this receptor to so many different diseases? This has been a "burning" question for many researchers both inside and outside of the field of the sigma-1 receptor.

The discovery that the sigma-1 receptor is an endoplasmic reticulum (ER) chaperone that resides mainly in the interface between the ER and mitochondrion, referred to as the MAM ([m]{.ul}itochondrion-[a]{.ul}ssociated ER [m]{.ul}embrane), has provided a piece of pivotal information to understanding the receptor's function. Further, the demonstration that sigma-1 receptors can translocate to other areas of cells or neurons, when stimulated by its agonists such as neurosteroids or psychostimulants, adds additional dimensions to understanding the receptor's mode of action and associated physiological functions. Thus, we know now that sigma-1 receptors function locally at the MAM but also remotely for example at the plasma membrane. However, whether those two modes of actions of sigma-1 receptors may relate themselves to so many different diseases remain to be totally clarified. For example, are there other modes of action of sigma-1 receptors? Or, modes of action may differ in different organs or tissues? Those are questions to be answered in future investigations.

Thus, it seems that the major hurdles to understanding the properties of sigma-1 receptors have been removed because of the advancements of technologies and associated findings as mentioned above. However, several fundamental questions concerning the sigma-1 receptor remain to be totally clarified. For example, what is the driving force that propels the translocation of sigma-1 receptors? What molecular mechanism(s) directs the underpinning targeting of sigma-1 receptors to the other parts of cell or neuron? What molecular mechanism(s) or specificity determines the targeted client protein that sigma-1 receptors will associate with either at the MAM or at remote parts of a cell? How do those molecular mechanisms, if fully established, relate to humans diseases?

The major discoveries on the fundamental properties and functions of the sigma-1 receptor mostly occur in the past five years after the receptor's initial discovery in 1982. The next decade should mark a critical and fruitful period when more important and pivotal findings will clarify and shape further our fundamental understanding of this receptor which has eluded our efforts for so long in the past.
